Drug delivery device with near-infrared light responsiveness

Abstract

The present invention relates to a near-infrared responsive drug delivery system, wherein a near-infrared responsive drug delivery system comprising a near-infrared responsive drug delivery formulation is provided, and the near-infrared responsive drug delivery formulation may include a near-infrared responsive material that generates heat in response to near-infrared rays, and a drug loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material.

Description

Technology Field

[0001] The present invention relates to a drug delivery system, and more specifically, to a near-infrared responsive drug delivery system implemented to include a near-infrared responsive material and a drug formulation, wherein drug release is controlled by irradiation conditions such as the intensity and duration of near-infrared stimulation, thereby enabling drug treatment suitable for the disease state of each individual patient. Background Technology

[0003] The market size for drug delivery systems is growing exponentially due to the surge in medical consumption and the development of drug-centered medical technology. As of 2021, the global drug delivery system market was estimated at $34.7 billion, and it is expected to grow to $71.75 billion by 2029, increasing at an average annual rate of 9%.

[0004] In the treatment of chronic progressive diseases such as glaucoma, osteoporosis, diabetes, and fibrosis of tissues surrounding implantable devices, the degree of disease progression and the therapeutic effect after drug administration vary from patient to patient. Therefore, there is a growing need for the development of controlled drug delivery technologies, such as those described in Public Patent No. 10-2022-0010982, “Drug-carrying formulation in which drug release is controlled by near-infrared rays and a waterproof outflow implant equipped with the same” (Published on January 27, 2022), and demand is also increasing significantly.

[0005] Furthermore, many pharmaceutical and biotech companies are actively investing in research on drug delivery systems that can produce ripple effects similar to new drugs while reducing the risks associated with new drug development.

[0006] Since near-infrared radiation has high skin penetration and is harmless to the human body, drug delivery systems utilizing it are expected to have very easy market entry. Therefore, research on drug delivery systems using near-infrared radiation is required.

[0007] Such background technology is technical information that the inventor possessed for the derivation of the present invention or acquired during the process of deriving the present invention, and it cannot be considered as prior art disclosed to the general public prior to the filing of the present invention. The problem to be solved

[0009] The embodiments disclosed in the present invention are devised in accordance with the aforementioned requirements, and the technical problem is to provide a near-infrared responsive drug delivery system implemented to release a drug upon near-infrared stimulation.

[0010] In addition, the technical objective of the embodiment of the present invention is to provide a near-infrared responsive drug delivery system implemented such that heat generated from a near-infrared responsive material by near-infrared stimulation modifies the structure of a formulation containing a drug, thereby enabling the release of the drug.

[0011] In addition, the embodiment of the present invention has the technical objective of providing a near-infrared responsive drug delivery system in which the drug release amount is controlled according to near-infrared irradiation conditions.

[0012] The technical objective is to provide a near-infrared responsive drug delivery system that enables drug treatment tailored to the individual patient's disease state.

[0013] The technical problems of the present invention are not limited to those mentioned above, and from the description below, those skilled in the art to which the present invention pertains will also clearly understand other problems intended by the present invention. means of solving the problem

[0015] As a technical means for achieving the aforementioned technical task, a near-infrared responsive drug delivery system comprising a near-infrared responsive drug delivery formulation is provided, wherein the near-infrared responsive drug delivery formulation may include a near-infrared responsive material that generates heat in response to near-infrared rays, and a drug loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material.

[0016] According to an example, the near-infrared responsive drug delivery system may further include a first substrate containing a near-infrared responsive substance.

[0017] According to an example, a first substrate containing a near-infrared responsive material and a drug-loaded formulation can be arranged in a stacked structure.

[0018] According to an embodiment, a first substrate containing a near-infrared responsive material and a drug-loaded formulation can be arranged side by side at a predetermined distance apart.

[0019] According to an embodiment, a first substrate containing a near-infrared responsive material and a drug-loaded formulation can be placed side by side in lateral contact.

[0020] According to an embodiment, the first substrate further contains a near-infrared responsive material, so that the near-infrared responsive material, the drug-loaded formulation, and the first substrate can be implemented as a single unit.

[0021] According to an example, the near-infrared responsive drug delivery formulation may further include a second substrate containing a drug-loading formulation.

[0022] According to an example, the near-infrared responsive drug delivery system may further include a container for accommodating a near-infrared responsive drug delivery formulation.

[0023] According to an example, a receiving portion for accommodating a near-infrared responsive drug delivery formulation may be formed in the container.

[0024] According to an example, a release port may be formed within the container that serves as a passage for releasing a drug to the outside of a near-infrared responsive drug delivery system.

[0025] According to an example, the release port may be formed adjacent to the drug-loaded formulation.

[0026] According to an example, the near-infrared responsive drug delivery system may further include a membrane placed inside or outside the container to cover the release port.

[0027] According to the example, the membrane may be disposed in a form attached to the outside of the container via an adhesive material.

[0028] According to the example, when the membrane is placed inside the container, it can be placed between the drug-loaded formulation and the container.

[0029] Specific details according to various examples of the present invention, other than the means for solving the problem mentioned above, are included in the description and drawings below. Effects of the invention

[0031] According to an embodiment of the present invention, a near-infrared responsive drug delivery system implemented to release a drug by near-infrared stimulation may be provided.

[0032] A near-infrared responsive drug delivery system according to an embodiment of the present invention can be implemented such that heat generated from a near-infrared responsive material by near-infrared stimulation deforms the structure of a formulation containing a drug, thereby enabling the release of the drug.

[0033] The near-infrared responsive drug delivery system according to the embodiment of the present invention has the effect of enabling drug treatment tailored to the individual patient's disease state, as the amount of drug released is controlled according to near-infrared irradiation conditions.

[0034] In addition, since the near-infrared responsive drug delivery system according to the embodiment of the present invention is implemented to release drugs by near-infrared rays that are harmless to the human body while having high skin permeability, safety and efficacy can be ensured and it can be easily applied to a drug delivery system.

[0035] In addition, since the near-infrared responsive drug delivery system according to the embodiment of the present invention has a novel structure that allows for drug treatment tailored to the individual patient's disease state while utilizing conventional drugs as is, it is expected to reduce the risks associated with new drug development while generating a ripple effect similar to that of a new drug.

[0036] In addition, since the composition of the near-infrared responsive drug delivery system according to the embodiment of the present invention is unitized, it has the advantage of being easy to commercialize and mass-produce, and accordingly, the near-infrared responsive drug delivery system according to the embodiment of the present invention can be stably supplied to demand centers requiring it.

[0037] The effects of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by those skilled in the art from the description below.

[0038] Since the problem to be solved, the means of solving the problem, and the effects mentioned above do not specify the essential features of the claim scope, the scope of rights of the claim is not limited by the matters described in the content of the invention. Brief explanation of the drawing

[0040] The drawings attached below are intended to aid in understanding embodiments of the present invention and provide embodiments together with a detailed description. However, the technical features of the present embodiment are not limited to specific drawings, and the features disclosed in each drawing may be combined with one another to form new embodiments. FIG. 1 is a drawing of a near-infrared responsive drug delivery system according to an embodiment of the present invention. FIG. 2 is a schematic diagram showing the configuration of a near-infrared responsive drug delivery system including a near-infrared responsive drug delivery formulation according to one embodiment of the present invention. FIG. 3 is a schematic diagram showing the structure of a near-infrared responsive drug delivery formulation according to another embodiment of the present invention. FIG. 4 is a schematic diagram showing the structure of a near-infrared responsive drug delivery formulation according to another embodiment of the present invention. Figures 5a and 5b show graphs of temperature change of a near-infrared responsive drug delivery system according to near-infrared irradiation with a duty cycle method applied. Figures 6a and 6b show graphs of in vitro drug release of a near-infrared responsive drug delivery system after near-infrared irradiation. Specific details for implementing the invention

[0041] The advantages and features of the present invention and the methods for achieving them will become clear by referring to the embodiments described below in detail together with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below but may be implemented in various different forms. These embodiments are provided merely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the invention, and the present invention is defined only by the scope of the claims.

[0042] Shapes, sizes, ratios, angles, numbers, etc. disclosed in the drawings for describing embodiments of the present invention are exemplary, and therefore the present invention is not limited to the depicted details. Throughout the specification, the same reference numerals refer to the same components. Furthermore, in describing the present invention, if it is determined that a detailed description of related prior art could unnecessarily obscure the essence of the present invention, such detailed description is omitted. Where terms such as "includes," "has," or "is made up" are used in this specification, other parts may be added unless "only" is used. Where a component is expressed in the singular, it includes cases where it is included in the plural unless specifically stated otherwise.

[0043] In interpreting the components, even if there is no separate explicit description of the error range, it is interpreted as including the error range.

[0044] In the case of an explanation regarding temporal relationships, where the temporal sequence is described using terms such as "after," "following," "next," or "before," cases that are not continuous may also be included unless "immediately" or "directly" is used.

[0045] Although terms such as "first," "second," etc., are used to describe various components, these components are not limited by these terms. These terms are used merely to distinguish one component from another. Accordingly, the first component mentioned below may be the second component within the technical scope of the present invention.

[0046] In describing the components of the present invention, terms such as first, second, A, B, (a), (b), etc., may be used. These terms are intended only to distinguish the components from other components, and the nature, order, sequence, or number of the components are not limited by these terms. Where it is stated that a component is "connected," "combined," or "joined" to another component, it should be understood that the component may be directly connected or joined to the other component, but that other components may be "interposed" between each component that may be indirectly connected or joined unless specifically stated otherwise.

[0047] "At least one" should be understood to include all combinations of one or more associated components. For example, the meaning of "at least one of the first, second, and third components" may be said to include not only the first, second, or third components, but also all combinations of two or more of the first, second, and third components.

[0048] The features of each of the various embodiments of this specification may be combined or combined with one another, either partially or wholly, and may technically enable various interlocking and operation. Each embodiment may be implemented independently of one another or may be implemented together in an associated relationship.

[0049] The embodiments of the present invention are described below through the attached drawings and examples. For the convenience of explanation, the scale of the components shown in the drawings differs from the actual scale and is therefore not limited to the scale shown in the drawings.

[0050] Hereinafter, a near-infrared responsive drug delivery system according to an embodiment of the present invention will be described with reference to the attached drawings.

[0052] FIG. 1 is a diagram showing a near-infrared responsive drug delivery system according to an embodiment of the present invention, and FIG. 2 is a diagram schematically showing the configuration of a near-infrared responsive drug delivery system including a near-infrared responsive drug delivery formulation according to an embodiment of the present invention.

[0053] Referring to FIGS. 1 and 2, a near-infrared responsive drug delivery system (1) (hereinafter, drug delivery system) according to an embodiment of the present invention may include a near-infrared responsive drug delivery formulation (100) (hereinafter, drug delivery formulation).

[0054] The drug delivery formulation (100) according to the embodiment is configured to deliver a drug and can be implemented to release the drug by thermal energy generated in response to near-infrared stimulation.

[0055] Since the drug delivery formulation (100) is implemented to release a drug in response to near-infrared stimulation, the amount of drug released from the drug delivery formulation (100) can be easily controlled by controlling the near-infrared irradiation conditions (e.g., irradiation time, irradiation intensity).

[0056] In this way, since the amount of drug released from the drug delivery formulation (100) can be easily controlled by controlling the near-infrared irradiation conditions, appropriate drug treatment can be administered according to the individual patient's disease state, thereby increasing the efficacy and efficiency of the treatment.

[0057] In addition, since the drug delivery formulation (100) according to the embodiment is implemented to release the drug by stimulation of near-infrared rays that are harmless to the human body and have high skin permeability, treatment can be performed while ensuring the safety of the patient.

[0058] In addition, the near-infrared responsive drug delivery system (1) or near-infrared responsive drug formulation (100) according to the embodiment has a new structure that allows for drug treatment according to the individual patient's disease state while utilizing conventional drugs as they are, so it can be expected to reduce the risk of new drug development and produce a ripple effect similar to that of a new drug.

[0059] The drug delivery formulation (100) according to the embodiment may include a near-infrared responsive material and a drug-loading formulation, and may further include a matrix. It is possible to implement various forms of the drug delivery formulation (100) depending on the combination method of the near-infrared responsive material, the drug-loading formulation, and the matrix.

[0060] For example, the drug-loading formulation may be a polymer-based formulation, indocyanine green (ICG) may be used as the near-infrared responsive material, and a polymer substrate (e.g., polydimethylsiloxane (PDMS)) may be used as the substrate. However, the types of substrates and near-infrared responsive materials are not limited to these.

[0061] Near-infrared responsive materials can be incorporated into a substrate in various ways, for example, by utilizing physical adsorption, chemical bonding, etc., but the methods of incorporating near-infrared responsive materials into a substrate are not limited to these.

[0062] According to the embodiments, the substrate may contain at least one of a near-infrared responsive material and a drug-loaded formulation. For example, the substrate may contain only the near-infrared responsive material, only the drug-loaded formulation, or both the near-infrared responsive material and the drug-loaded formulation.

[0063] According to the embodiments, the near-infrared responsive material and the drug-loaded formulation may be arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact.

[0064] According to an embodiment, a substrate containing a near-infrared responsive material and a drug-loaded formulation may be arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact.

[0065] According to the embodiment, a near-infrared responsive material and a substrate containing a drug-loaded formulation may be arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact.

[0066] According to the embodiment, a substrate containing a near-infrared responsive material and a substrate containing a drug-loaded formulation may be arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact.

[0067] According to an embodiment, in a case where both a near-infrared responsive material and a drug-loaded formulation are contained in a single substrate, the near-infrared responsive material and the drug-loaded formulation may be arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact.

[0068] According to an embodiment, the drug delivery formulation (100) may include a substrate (101) loaded with a near-infrared responsive material (hereinafter, near-infrared responsive material substrate), and a drug-loaded formulation (102), and the near-infrared responsive material substrate (101) and the drug-loaded formulation (102) may be arranged in a stacked structure.

[0069] The drug delivery formulation (100) according to the embodiment may be composed of a near-infrared responsive material and a drug-loading formulation (102) without including a substrate.

[0070] However, the arrangement of the near-infrared responsive material substrate (101) and the drug-loaded formulation (102) is not limited to this, and for example, the near-infrared responsive material substrate (101) and the drug-loaded formulation (102) may be arranged side by side with a predetermined distance between them or with their sides in contact.

[0071] For example, the near-infrared responsive material substrate (101) and the drug-loading formulation (102) may be formed in a plate shape, but are not limited thereto.

[0072] According to an embodiment, a near-infrared responsive material mounted on a near-infrared responsive material substrate (101) generates heat due to external near-infrared rays, and as the structure of the drug-loaded formulation (102) is deformed by the heat generated from the near-infrared responsive material, the drug within the formulation is released. For example, the drug-loaded formulation (102) may expand and become flexible during the process of structural deformation.

[0073] As previously explained, the drug delivery formulation (100) can be implemented in various forms depending on the combination method of the near-infrared responsive material, the drug-loading formulation, and the substrate.

[0074] FIG. 3 is a schematic diagram showing the structure of a near-infrared responsive drug delivery formulation according to another embodiment of the present invention, and FIG. 4 is a schematic diagram showing the structure of a near-infrared responsive drug delivery formulation according to yet another embodiment of the present invention.

[0075] As illustrated in FIG. 3, the drug delivery formulation (100′) may be implemented in a form in which a substrate (113) contains a near-infrared responsive material (111) and a drug-loaded formulation (112). That is, the drug delivery formulation (100) may include a substrate (113) containing a near-infrared responsive material (111) and a drug-loaded formulation (112), and the near-infrared responsive material (111), the drug-loaded formulation (112), and the substrate (113) may be implemented as a single unit.

[0076] For example, a substrate (113) containing a near-infrared responsive material (111) and a drug-loading formulation (112), i.e., a drug delivery formulation (100′), may be formed in the form of a plate, but is not limited thereto.

[0077] Since the near-infrared responsive material (111) reacts with the near-infrared responsive material (111) to generate heat, and the structure of the formulation is deformed by the heat generated from the near-infrared responsive material (111) to release the drug, it is desirable that the near-infrared responsive material (111) contained within the substrate (113) and the drug-loaded formulation (112) be distributed in a uniformly mixed form for uniform drug release.

[0078] As illustrated in FIG. 4, the drug delivery formulation (100″) can be implemented in a form in which a near-infrared responsive material (121) and a drug-loading formulation (122) are each wrapped in a substrate (123).

[0079] That is, the drug delivery formulation (100″) may include a substrate (first substrate) (123-1) containing a near-infrared responsive material (121), and a substrate (second substrate) (123-2) containing a drug-loading formulation (122).

[0080] For example, a first substrate (123-1) containing a near-infrared responsive material (121) and a second substrate (123-2) containing a drug-loading formulation (122) may be arranged in a stacked structure. However, the arrangement of the first substrate (123-1) containing the near-infrared responsive material (121) and the second substrate (123-2) containing the drug-loading formulation (122) is not limited thereto, and the first substrate (123-1) containing the near-infrared responsive material (121) and the second substrate (123-2) containing the drug-loading formulation (122) may be arranged side by side with a predetermined distance between them or with their sides in contact.

[0081] For example, the near-infrared responsive material (121) contained in the first substrate (123-1) and the drug-loading formulation (122) contained in the second substrate (123-2) can each be evenly distributed for efficient release of the drug.

[0082] For example, the first substrate (123-1) containing a near-infrared responsive material (121) and the second substrate (123-2) containing a drug-loading formulation (122) may be formed in a plate shape, but are not limited thereto.

[0083] As such, since the components forming the drug delivery formulation according to the embodiment of the present invention are unitized, productization and mass production are easy, and the drug delivery formulation can be stably supplied to demand centers requiring it. Furthermore, the same effect can also be expected for a near-infrared responsive drug delivery body (1) containing the drug delivery formulation.

[0084] Referring again to FIG. 2, the drug delivery system (1) according to the embodiment may further include a reservoir (200) in addition to the drug delivery formulation (100). The reservoir (200) is intended to accommodate the drug delivery formulation (100), and it may be formed in a structure capable of accommodating the drug delivery formulation (100).

[0085] According to an embodiment, the container (200) can prevent damage to surrounding tissues within the human body caused by heat generated by a near-infrared responsive material, and may be, for example, a PDMS-based container, but is not limited thereto.

[0086] A container (200) according to an embodiment may include a first container (210) and a second container (220) to accommodate a drug delivery formulation (100), and the first container (210) and the second container (220) are combined, and the drug delivery formulation (100) may be accommodated within the combined first and second containers (210, 220).

[0087] According to an embodiment, the first container (210) is positioned on the side of the near-infrared responsive material substrate (101) and the second container (220) is positioned on the side of the drug-loading formulation (102), and the drug-delivery formulation (100) can be accommodated in the container (200) in such a manner that the first container (210) and the second container (220) surround the side of the drug-delivery formulation (100).

[0088] For example, a receiving portion (201) for stable reception of a drug delivery formulation (100) may be formed within the container (200). The receiving portion (201) may be formed in at least one of the first container (210) and the second container (220).

[0089] As in the example, when a drug delivery formulation (100) is contained in a container (200), the drug may not be released into the human body by the container (200). To solve this problem, a release port (202) may be formed in the container (200) to allow the drug to be released into the human body.

[0090] Since the discharge port (202) serves as a passage for the drug to be discharged to the outside of the near-infrared responsive drug delivery system (1), it is preferable that it be formed adjacent to the drug-loaded formulation (102). Accordingly, the discharge port (202) according to the embodiment may be formed in a second container (220) located on the side of the drug-loaded formulation (102).

[0091] Depending on the structure of the drug delivery formulation (100), the location where the release port (202) is formed may vary.

[0092] For example, when a drug delivery formulation (100') with a structure as in FIG. 3 is contained in a container (200), a discharge port (202) may be formed in at least one of the first container (210) and the second container (220).

[0093] For example, when a drug delivery formulation (100) with a structure as in FIG. 4 is contained in a container (200), the discharge port (202) may be formed in the container located on the side of the substrate (second substrate) (123-2) containing the drug-loaded formulation (122) among the first and second containers (210, 220).

[0094] Figure 2 shows that one discharge port (202) is formed, but is not limited thereto, and multiple discharge ports (202) may be formed in the container (200).

[0095] The drug delivery system (1) according to the embodiment may further include a membrane (or thin film) (300).

[0096] The membrane (300) can be placed inside or outside the container (200) and can prevent loss of the drug-loaded formulation (100).

[0097] According to an embodiment, the membrane (300) may be placed outside the container (200) to cover the discharge port (202). For example, the membrane (300) placed outside the container (200) may be placed in a form that is attached to the outside of the container (200) via an adhesive material so that the membrane (300) does not easily detach from the container (200).

[0098] According to an embodiment, when the membrane (300) is placed inside the container (200), it may be placed between the drug-loaded formulation (100) and the container (200) to cover the discharge port (202).

[0099] The membrane (300) can be placed between the drug-loading formulation (100) and the first and second containers (210, 220) in which the discharge port (202) is formed, and placed on the drug transport path.

[0100] If the membrane (300) is thick, the amount of drug absorbed by the membrane (300) increases, and the time it is released to the outside through the release port (202) becomes longer. And, if the membrane (300) is thin, the amount of drug absorbed by the membrane (300) decreases, and the time it is released to the outside through the release port (202) becomes shorter. Therefore, the time or amount of drug released can be controlled according to the thickness of the membrane (300).

[0101] If the membrane (300) is smaller than the discharge port (202), it can escape through the discharge port (202), so it is desirable for the membrane (300) to have a size that can cover the entire discharge port (202).

[0102] In this way, since the membrane (300) is placed on the drug transport path, if the membrane (300) is formed in a structure where the drug cannot move, the drug cannot be released outside the container (200). Therefore, the membrane (300) is formed in a structure where the drug can move, and for example, a porous membrane (300) may be applied.

[0103] FIG. 2 illustrates a membrane (300) placed between a drug-loaded formulation (100) and a second container (220), but is not limited thereto.

[0104] For example, when a drug delivery formulation (100') with a structure as in FIG. 3 is contained in a container (200), depending on the location of the discharge port (202) formed in the container (200), the membrane (300) may be placed at least one of the positions between the drug delivery formulation (100') and the first container (210), and between the drug delivery formulation (100') and the second container (220).

[0105] For example, when a drug delivery formulation (100) with a structure as in FIG. 4 is contained in a container (200), depending on the location of the discharge port (202) formed in the container (200), the membrane (300) may be placed between the first container (210) and the substrate (second substrate) (123-2) containing the drug-loaded formulation (122), or between the second container (220) and the substrate (second substrate) (123-2) containing the drug-loaded formulation (122).

[0107] Preparation Example

[0108] Sylgard 184 TM Each component of the near-infrared responsive drug delivery system (1) was prepared using a silicone kit, and PDMS was used as the substrate.

[0109] For the near-infrared responsive material substrate (101), reagent A and indocyanine green (ICG), a near-infrared responsive material, were mixed in a weight ratio of 100:1 (weight / weight, (w / w)). The drug-loaded formulation (102) was prepared as a drug-loaded particle-based formulation and a drug-loaded film-based formulation, and dexamethasone (DEX) was used as the drug.

[0110] The drug-loaded particle-based formulation was prepared by manufacturing DEX-PLGA particles using the solid-oil-water solvent evaporation method and forming them into a tablet, and the drug-loaded film-based formulation was prepared by manufacturing a DEX-PLGA film using the solvent casting method.

[0111] Specifically, to describe the method for manufacturing DEX-PLGA particles and DEX-PLGA tablets, PLGA and DEX were added to 7 ml of methylene chloride in a weight ratio (w / w) of 50:1 to create a homogeneous solution, which was then mixed with 7 ml of 1% polyvinyl alcohol (PVA) solution and emulsified using a dismembrantor to prepare a homogeneous suspension. Then, the suspension was added to 100 ml of 1% PVA solution, and the solvent was evaporated under reduced pressure while stirring at 400 rpm for 1 hour to produce DEX-PLGA particles.

[0112] Subsequently, a particle suspension was prepared by mixing DEX-PLGA particles at a concentration of 10 mg / ml in a 0.25% polyvinyl alcohol solution or a 5% trehalose solution, and then 10 μl of the suspension was placed in a container (200) containing a near-infrared responsive material substrate (101) and freeze-dried to produce a near-infrared responsive drug delivery system (1).

[0113] In the case of the DEX-PLGA film, PLGA, polyethylene glycol, and DEX were added to acetone in a weight ratio of 50:5:1 (w / w / w) to create a homogeneous solution, which was then poured into a mold and dried. Then, a container (200) containing the DEX-PLGA film, PDMS layer, and a near-infrared responsive material substrate (101) was assembled to produce a near-infrared responsive drug delivery system (1).

[0115] Experimental Example

[0116] Near-infrared radiation was irradiated onto a near-infrared responsive drug delivery system (1) using a near-infrared irradiation device (Ocla URI, LVI Technology), and the temperature changes inside and outside the near-infrared responsive drug delivery system (1) before and after irradiation were observed. In the method of irradiating near-infrared radiation, a duty cycle method was applied in which near-infrared radiation is irradiated for a certain period of time and then turned off. Near-infrared radiation was irradiated by setting the near-infrared intensity to 1~2 W, the duration of near-infrared irradiation to 10~15 seconds, and the rest time to 30~60 seconds.

[0117] Figures 5a and 5b show graphs of temperature change of a near-infrared responsive drug delivery system according to near-infrared irradiation with a duty cycle method applied.

[0118] Figure 5a is a graph of the temperature change of a near-infrared responsive drug delivery system when the near-infrared irradiation duration is set to 15 seconds and the rest time to 60 seconds, and Figure 5b is a graph of the temperature change of a near-infrared responsive drug delivery system when the near-infrared irradiation duration is set to 10 seconds and the rest time to 30 seconds.

[0119] Figures 6a and 6b show graphs of in vitro drug release of a near-infrared responsive drug delivery system after near-infrared irradiation.

[0120] Figure 6a is a graph showing the in vitro drug release of a near-infrared responsive drug delivery system in hours after near-infrared irradiation, and Figure 6b is a graph showing the in vitro drug release of a near-infrared responsive drug delivery system in days after near-infrared irradiation.

[0121] To obtain an in vitro drug release graph of a near-infrared responsive drug delivery system after near-infrared irradiation, the near-infrared responsive drug delivery system was pre-wetted in 10 mM pH 7.4 phosphate buffer saline (PBS) one day prior to near-infrared irradiation. Near-infrared irradiation was performed with the distance between the near-infrared light source and the near-infrared responsive drug delivery system fixed at 15 mm and the size of the near-infrared light spot fixed at 20 mm in diameter. The near-infrared intensity was set to 1–3 W, and the duration of the near-infrared irradiation was set to 10–30 min.

[0123] Although embodiments of the present invention have been described in more detail with reference to the attached drawings, the present invention is not necessarily limited to these embodiments and may be modified in various ways within the scope of the technical spirit of the present invention. Accordingly, the embodiments disclosed in this specification are intended to explain, not limit, the technical spirit of the present invention, and the scope of the technical spirit of the present invention is not limited by these embodiments. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of protection of the present invention shall be interpreted by the claims, and all technical spirits within an equivalent scope shall be interpreted as being included within the scope of rights of the present invention. Explanation of the symbols

[0125] 1: Near-infrared responsive drug delivery system 100, 100′, 100″: Near-infrared responsive drug delivery formulations 101: Near-infrared responsive material substrate 102: Drug-loaded formulation 111: Near-infrared responsive material 112: Drug-loaded formulation 121: Near-infrared responsive material 122: Drug-loaded formulation 123: Substrate 123-1: First Temperament 123-2: Second Temperament 200: Courage 201: Reception Section 202: Discharge port 210: First container 220: Second vessel 300: Membrane

Claims

Claim 1 A near-infrared responsive drug delivery formulation; a container formed by combining a first container having a receiving portion and a second container having an emission port for releasing a drug to the outside, and containing the near-infrared responsive drug delivery formulation; and a membrane formed inside or outside the container to cover the emission port, wherein the near-infrared responsive drug delivery formulation comprises a near-infrared responsive material that generates heat in response to near-infrared rays; and a drug-loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material. Claim 2 A near-infrared responsive drug delivery system according to claim 1, wherein the near-infrared responsive material and the drug-loading formulation are arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact. Claim 3 A near-infrared responsive drug delivery system according to claim 1, further comprising a first substrate containing the near-infrared responsive material. Claim 4 In claim 3, a near-infrared responsive drug delivery system in which the first substrate containing the near-infrared responsive material and the drug-loading formulation are arranged in a stacked structure. Claim 5 In claim 3, a near-infrared responsive drug delivery system in which the first substrate containing the near-infrared responsive material and the drug-loaded formulation are arranged side by side at a predetermined distance apart. Claim 6 In claim 3, a near-infrared responsive drug delivery system in which the first substrate containing the near-infrared responsive material and the drug-loaded formulation are arranged side by side in lateral contact. Claim 7 In claim 3, the first substrate further comprises the drug-loading formulation, and the near-infrared responsive material, the drug-loading formulation, and the first substrate are integrally implemented in a near-infrared responsive drug delivery system. Claim 8 In claim 7, the near-infrared responsive material and the drug-loading formulation contained within the first substrate are arranged in a stacked structure, or are arranged side by side with a predetermined spacing apart or in lateral contact, forming a near-infrared responsive drug delivery system. Claim 9 In claim 1, the near-infrared responsive drug delivery formulation further comprises a second substrate containing the drug-loading formulation. Claim 10 In claim 9, the near-infrared responsive material and the second substrate containing the drug-loading formulation are arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact, forming a near-infrared responsive drug delivery system. Claim 11 In claim 3, the near-infrared responsive drug delivery formulation further comprises a second substrate containing the drug-loading formulation. Claim 12 A near-infrared responsive drug delivery system according to claim 11, wherein the first substrate containing the near-infrared responsive material and the second substrate containing the drug-loading formulation are arranged in a stacked structure, or arranged side by side with a predetermined spacing apart or in lateral contact. Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 In claim 1, the emission port is a near-infrared responsive drug delivery system formed adjacent to the drug-loading formulation. Claim 17 delete Claim 18 In claim 1, the membrane is a near-infrared responsive drug delivery system disposed between the drug-loaded formulation and the second container when disposed inside the container.

Images